Key result
New trial tests if pharmacist access to renal function reduces bleeding in DOAC users.
Why the study?
Renal impairment increases bleeding risk in DOAC users, but community pharmacists often have limited access to renal function information during dispensing to optimize drug choice and dosage.
Does providing community pharmacists with systematic access to patients' renal function information reduce clinically relevant bleeding in DOAC users?
Population
Planned 1920 DOAC users across 96 community pharmacies
Comparison
Systematic community pharmacist access to renal function vs usual care
Design
Prospective multicenter cluster-randomized trial protocol
Follow-up
6 months
Authors
Loading...
May improve bleeding safety for DOAC users if effective; leaves open whether pharmacist renal data access reduces clinically relevant bleeding.
RCT (n=1,920)
cluster
Yes
Does providing community pharmacists with systematic access to patients' renal function information reduce clinically relevant bleeding in DOAC users?
Badran et al. (2026) conducted an RCT in Direct oral anticoagulant (DOAC) users (n=1,920). Systematic access to renal function information vs. Usual care was evaluated on Occurrence of clinically relevant bleeding—major and nonmajor—occurring within three months after DOACs dispensing. Systematic access to renal function information for community pharmacists will be evaluated in a cluster randomized trial of 1,920 DOAC users to assess its impact on clinically relevant bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: